“CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting”, J of Skin, vol. 7, no. 2, p. s174, Mar. 2023, doi: 10.25251/skin.7.supp.174.